Recently, Zhuhai Trinomab Biotech Co., Ltd. (Hereinafter referred to as “Trinomab”) announced the completion of Pre-IPO round of financing with total of approximately 750 millions of RMB. This round of financing is jointly led by the Gree Gold Investment and the Xicheng Jinrui and also contributed from Efung Capital and Shenyin Wanguo, and the original shareholders including Kangzhe Pharmaceutical, Wuxi Guolian and Jinhang Group continue to invest. Funds raised from this round of financing will be mainly used to promote and facilitate products in Trinomab Research Pipeline toward CMC, IND filing, and clinical trials , construction of production facilities and the development of marketing capability.
Mr. Zheng Weihong, Co-founder, CEO and President of Trinomab, said: “Since the establishment of Trinomab at the end of 2015, the company has always focused on creation of clinical value by developing innovative drugs highly differentiated from the others. We firmly believe that with tremendous effort from Trinomab staff and support of from our partners, Trinomab will have opportunity to move its products to patients and clinics in faster and more steadily progress.”
Trinomab Biotech Co., Ltd. Is currently a clinical stage biopharmaceutical company with a global expansion perspective. The company is mainly engaged in R&D of inovative fully native human mAb drugs. The core technology of the company is known as the fourth-generation fully human antibody technology HitmAb®. Based on this technology, the company has explored more than 20 new natural human monoclonal antibodies against infectious diseases and cancers, among which TNM002 injection, a monoclonal antibody against tetanus toxin, has entered phase III clinical trials. TNM001 has been granted the Breakthrough Therapy from the China CDE and Fast Track Designation from US FDA. TNM002 injection is the first in its class in the world as an anti-tetanus toxin monoclonal antibody entering the clinical. Another self-developed recombinant anti-respiratory syncytial virus (RSV) fully human monoclonal antibody TNM001 injection was approved by both China NMPA and US FDA to enter clinical trials and now is reach to Phase Ib/IIa clinical trial stage starting in October 2022. In addition, several more products are almost ready to be filed for IND, and nearly 10 more projects are under development.
To meet the needs for industrialization and commercialization of products in its pipelines, Trinomab has already built about 23,000㎡ GMP antibody production facility in Zhuhai International Health Harbor, which has enough capability to produce materials for the pre-clinical use for Trinomab’s first 4-5 products at this stage.
Li Ling, Senior Investment Manager of Gree Gold Investment, said: There is a huge clinical demand for preventive treatment of tetanus. Due to the shortage of plasma supply in China, there is a large shortage of specific anti-tetanus human blood immunoglobulin. Under the leadership of Dr. HUAXIN LIAO and Mr. Zheng Weihong, Trinomab as an innovative biopharmaceutical enterprise incubated and grown locally in Zhuhai, has explored several anti-infective antibody drugs and successfully promoted them to clinical trials. Trinomab’s recombinant tetanus antibody drugs will effectively solve the accessibility problems in related fields. The Gree Gold Investment has always been at the forefront of scientific and technological innovation, investing in innovative enterprises that are in line with the national strategy and Zhuhai's “industry first” development direction. We are firmly optimistic about the development of the company, and we hope to contribute to the development of the biomedical industry in China and Zhuhai together with Trinomab.
Chen Leiwen, Managing Partner of Xicheng Jinrui, said: The natural fully human antibody drug discovery platform of Trinomab has been demonstrated as efficient innovative drug pipeline development capabilities, which will help China Pharmaceutical to take a solid step on the road from "micro-innovation" to "global innovation". We look forward to witnessing the continuous breakthrough efficacy of the company's innovative drug pipeline and bringing clinical benefits to the vast number of patients.
About Gree Gold Investment
Gree Gold Investment was established in 2017, with a registered capital of 13 billion RMB. It is the first state-owned capital investment and operation platform in Zhuhai, an important subsidiary wholly owned by Gree Group and the main platform for industrial investment and capital operation. In October 2022, it was awarded with AAA credit rating. Since its establishment five years ago, Gree Gold Investment has adhered to the main direction of the "4 + 3" industrialization ( new generation information technology, new energy, integrated circuits, biomedicine and health, and the three advantageous industries of intelligent household appliances, equipment manufacturing and fine chemicals) promoted by Zhuhai metropolitan government, focusing on industrial investment. Enabling investment has injected strong momentum into Zhuhai's industrial transformation and upgrading and high-quality economic development, and won the title of “2022 Top 30 State-Owned Partners in China's Equity Investment Market”.
About Xicheng Jinrui
Beijing Xicheng Jinrui Equity Investment Fund Management Co., Ltd. was established in 2018, it is a market-oriented professional investment institution with state-owned background initiated by Beijing Financial Street Capital Operation Center, China State-owned Enterprise Structural Adjustment Fund Co., Ltd. and China Reform Fund Management Co., Ltd. Focus on high-quality enterprises in the fields of information security, new energy, industrial intelligence, medical health and enterprise services.
About Efung Capital
Shenzhen Efung Capital is one of the earliest venture capital institutions that specialized in biomedicine investment in China. Efung has a high-caliber management team and an experienced investment team, which consist of MDs/PhDs graduated from professional institutions at home and abroad. It focuses on medical and healthcare sectors, especially in VC and PE investment in biopharmaceuticals and high-end medical devices. Throughout these years, Efung has explored profoundly the potentials of healthcare industry, and has invested over 50 prominent companies globally, such as Chipscreen Bioscience, Frontier Biotech, Ascentage Pharma, Lifotronic Technology, Apexigen and Centrexion et al. Efung Capital has demonstrated a solid track record, and has achieved strong revenue and earnings growth.
About Shenyin Wanguo Investment
Shenyin Wanguo Investment Co., Ltd. is a wholly-owned subsidiary of Shenwan Hongyuan Securities Co., Ltd., which was established on April 9, 2009 with the approval of China Securities Regulatory Commission. It is currently a private equity fund management subsidiary of the securities company, to expand all kinds of private equity fund management business by relying on the strong background and strong support of shareholders such as CIC and Central Huijin.
